Skip to content
ATLAS PREP HQ
Longevity

MOTS-c

Mitochondrial ORF of the 12S rRNA-c, a mitochondrial-derived 16-amino-acid peptide

Mitochondrial-derived peptide research focused on metabolic signaling, glucose handling, and cellular energy.

Preclinical Evidence

Route

Subcutaneous research use.

Common format

10 mg vial

Research focus

insulin sensitivity

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Longevity research motifLongevity

MOTS-c in 30 seconds

Atlas Fast Read

What it is

Mitochondrial ORF of the 12S rRNA-c, a mitochondrial-derived 16-amino-acid peptide

Why people care

Mitochondrial-derived peptide research focused on metabolic signaling, glucose handling, and cellular energy.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

MOTS-c is scientifically interesting for insulin sensitivity, exercise adaptation, but the current case is driven mainly by cell and animal data.

Overview

What is MOTS-c?

MOTS-c is mitochondrial ORF of the 12S rRNA-c, a mitochondrial-derived 16-amino-acid peptide. Mitochondrial-derived peptide research focused on metabolic signaling, glucose handling, and cellular energy.

MOTS-c was identified in 2015 as a mitochondrial-derived peptide encoded within mitochondrial 12S rRNA. It quickly became a research target for metabolic adaptation, aging, and exercise-related signaling.

Mechanism

How it works

Acts as a mitochondrial stress signal that can translocate to the nucleus and influence AMPK, folate/purine metabolism, insulin sensitivity, and stress-response genes. Much of the mechanistic evidence is preclinical.

Research areas

insulin sensitivityexercise adaptationmitochondrial stress signalingaging

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

As of 2026, meaningful human interventional evidence for administered MOTS-c remains very limited. Human observational studies link endogenous MOTS-c biology and genetic variation to metabolic phenotypes, but that is not equivalent to demonstrating benefit from injections.

Preclinical evidence

Mouse studies report improved insulin sensitivity, exercise capacity, metabolic flexibility, and stress adaptation, partly through AMPK and nuclear signaling. These findings drive interest but have not been validated by human dosing trials.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community research reference: 200–1,000 mcg/day with gradual titration. No validated human therapeutic dose exists.

Frequency

Once daily in the community protocol.

Timing

No established time-of-day requirement; exercise-related timing remains speculative.

Route

Subcutaneous research use.

Cycle length

8–12 weeks

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; minimize freeze-thaw.

Monitoring

Fasting glucose/HbA1c, CMP, CBC, weight/body composition and exercise-performance markers may document research outcomes; no validated clinical monitoring standard exists.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety data are insufficient. Potential adverse effects include injection-site reactions, headache, fatigue, dizziness, nausea and unknown long-term effects on gene regulation, growth, metabolism or immune function.

Contraindications

No validated human contraindication profile exists. Avoid use outside research oversight in pregnancy/breastfeeding, active malignancy, significant organ disease or known hypersensitivity.

Interactions

Formal drug-interaction studies are absent or very limited. Interactions with anticancer, endocrine, metabolic and immunomodulatory therapies are unknown.

Stacks

Common stacks

MOTS-c + NAD+

Longevity research pairing aimed at mitochondrial signaling plus cellular redox/coenzyme availability.

No clinical evidence that the combination improves longevity or performance.

MOTS-c + SS-31

Pairs a mitochondrial-derived signaling peptide with a cardiolipin-targeted mitochondrial peptide.

Mechanistic/preclinical rationale; combination not clinically validated.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

MOTS-c is scientifically interesting for insulin sensitivity, exercise adaptation, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide